Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Radiation in High-Risk HR+/HER2- Breast Cancer
NCT05996107Phase 1Active, not recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Feb 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in breast cancer, sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Dose Limiting Toxicity. Started Feb 2024; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05996107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05996107.